Targeting care in Barrett's oesophagus

Area of Science:

• Gastroenterology
• Oncology
• Molecular Pathology

Background:

• Barrett's esophagus is a major risk factor for esophageal adenocarcinoma (OAC).
• Most patients with Barrett's esophagus do not develop OAC, yet surveillance is broadly applied.
• Early detection of OAC and its precursors improves patient outcomes.

Purpose of the Study:

• To address the discrepancy between the number of patients needing surveillance and those undergoing it.
• To explore improved risk stratification methods for Barrett's esophagus.
• To investigate the role of molecular biomarkers in identifying high-risk individuals.

Main Methods:

• Current risk stratification relies on clinical, endoscopic, and histopathological findings.
• Histopathology can be imperfect, necessitating molecular confirmation.
• p53 immunohistochemistry is a clinically useful molecular biomarker.

Main Results:

• Molecular stratification is increasingly important for accurate risk assessment.
• Other molecular biomarkers are expected to become beneficial in the future.
• Non-endoscopic methods like Cytosponge may integrate molecular biomarkers and histopathology.

Conclusions:

• Accurate risk stratification is crucial for optimizing surveillance programs for Barrett's esophagus.
• Molecular biomarkers, including p53 immunohistochemistry, enhance diagnostic accuracy.
• Emerging non-endoscopic technologies hold promise for population screening and surveillance.